KH-815

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameKH-815

Drug Alias NameKH815KH-815

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAnti-Trop-2DNA topoisomerase I inhibitorsRNA polymerase II inhibitors

TargetsTumor-associated calcium signal transducer 2DNA topoisomerase IRNA polymerase II

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesChengdu Kanghong Biotechnologies Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Kanghong Biotechnologies Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A